RxDoctor Payments DataLook up a doctor →

Francesco Vetri

Pain Medicine · Decatur, ILNPI 1427323864

Payments from drug & device makers

$80,479in general payments, 2019–2025

Across 483 payments — averaging $166.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$49K
  • Avanos Medical$12K
  • Tersera Therapeutics LLC$5K
  • Medtronic$4K
  • Averitas Pharma Inc.$3K
  • Nevro Corp.$968
  • plus $7K from 31 others

What the payments were for

  • Consulting fees$4,53626%
  • Travel & lodging$2,00011%
  • Food & beverage$10,96963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,479 in reported general payments places this provider in the 95th percentile of 233 pain medicine providers in Illinois.

See all pain medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$100,319
Medicare patients
186
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl23$36,784
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen737$22,234
MovantikNaloxegol Oxalate45$19,156
Buprenorphine49$16,462
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen329$11,332
SymproicNaldemedine Tosylate20$8,863
BelbucaBuprenorphine Hcl19$8,344
Lidocaine32$5,221
Xtampza ErOxycodone Myristate12$4,835
Pregabalin201$3,646
Gabapentin172$3,275
Fentanyl26$2,634
Tizanidine Hcl287$2,491
Morphine Sulfate ErMorphine Sulfate94$2,198
Morphine Sulfate76$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er$169$49,96354 claims
Redhill Biopharma Inc.Movantik$16$19,15645 claims
Shionogi IncSymproic$24$8,86320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 pain medicine providers in Illinois.

Other pain medicine in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →